| Company Name: |
Suzhou Zhixin Biotechnology Co., Ltd.
|
| Tel: |
0512-65118909 18100677375 |
| Email: |
sales@szzxbio.com |
| Products Intro: |
Product Name:FR-167356
CAS:174185-16-1
Purity:98%+ Package:1g;10g;100g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:FR-167356
CAS:174185-16-1
Purity:99.00% Package:1mg;5mg;10mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:FR-167356
CAS:174185-16-1
Purity:99.74% Package:1mg/RMB 828;5mg/RMB 2000;10mg/RMB 2800
|
FR-167356 manufacturers
- FR-167356
-
- $118.00 / 1mg
-
2026-04-20
- CAS:174185-16-1
- Min. Order:
- Purity: 99.74%
- Supply Ability: 10g
|
| | FR-167356 Basic information |
| Product Name: | FR-167356 | | Synonyms: | FR-167356;Benzamide, 2,6-dichloro-N-[3-(1-hydroxy-1-methylethyl)-2-methyl-7-benzofuranyl]- | | CAS: | 174185-16-1 | | MF: | C19H17Cl2NO3 | | MW: | 378.25 | | EINECS: | | | Product Categories: | | | Mol File: | 174185-16-1.mol |  |
| | FR-167356 Chemical Properties |
| Boiling point | 422.7±40.0 °C(Predicted) | | density | 1.385±0.06 g/cm3(Predicted) | | pka | 11+-.0.43(Predicted) |
| | FR-167356 Usage And Synthesis |
| Uses | FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss[1]. | | in vivo | FR-167356 (200 mg/kg; p.o.; daily, for 10 days; male C57BL/6 mice with B16-F10 xenografts) inhibits tumor growth and reduces MMP9 expression[1].
FR-167356 (200 mg/kg; p.o.; daily, for 10 days; male C57BL/6 mice with B16-F10 xenografts) reduces bone metastasis compared to untreated group[1].
| Animal Model: | male C57BL/6 mice with B16-F10 xenografts[1] | | Dosage: | 200 mg/kg | | Administration: | Oral administration; daily, for 10 days | | Result: | Reduced the expression of MMP9 and reduced bone metastasis. |
| | References | [1] Nishisho T, et, al. The a3 isoform vacuolar type H-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55. DOI:10.1158/1541-7786.MCR-10-0449
[2] Niikura K, et, al. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88. DOI:10.1359/JBMR.050517 |
| | FR-167356 Preparation Products And Raw materials |
|